Study wrapper · #970
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
Son JW, le Roux CW, Blüher M, et al. Endocrine reviews. 2026.
DOI: 10.1210/endrev/bnaf036PubMed: 41054801
SupportedReviewMentions: RetatrutideMentions: CagrilintideMentions: SemaglutideMentions: Tirzepatide
Editor's note
A broad review of emerging GLP-1-based and multireceptor agents for obesity and diabetes. Several tracked peptides appear, including retatrutide, CagriSema (cagrilintide plus semaglutide), and tirzepatide as an established benchmark. Useful landscape context rather than primary data.
Plain-language abstract
This review surveys next-generation GLP-1-based therapies for type 2 diabetes and obesity, including retatrutide, cagrilintide, semaglutide, and tirzepatide.
Related coverage
Supported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.)n=——2026
Weak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Behavioural brain researchn=——2026
Supported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High blood pressure & cardiovascular preventionn=——2026